Josephine van Dongen

Chapter 5 130 References 1. Briggs-Steinberg C, Shah S, Perinatol AJ. Rationale for In-Neonatal Intensive Care Unit Administration of Live, Attenuated Rotavirus Vaccination Rotavirus Vaccines. Am J Perinatol. Published online 2018. doi:10.1055/s-0038-1660463 2. Bruijning-Verhagen P, Mangen M-JJ, Felderhof M, et al.Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med. 2013;11. doi:10.1186/1741-7015-11-112 3. Kilich E, Sadarangani M. Use of rotavirus vaccines in preterm babies on the neonatal unit. Expert Rev Vaccines. 2016;15(12):1463-1465. doi:10.1080/14760584.2016.1216318 4. Dahl RM, Curns AT, Tate JE, Parashar UD. Effect of rotavirus vaccination on acute diarrheal hospitalizations among low and very low bir th weight US infants, 2001-2015. Pediatr Infect Dis J . 2018;37(8):817-822. doi:10.1097/INF.0000000000001930 5. Vesikari T, Matson DO, Dennehy P, et al. Safety and Efficacy of a Pentavalent Human– Bovine (WC3) Reassor tant Rotavirus Vaccine. N Engl J Med . 2006;354(1):23-33. doi:10.1056/ NEJMoa052664 6. Omenaca F, Sarlangue J, Szenborn L, et al. Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Preterm European Infants: A Randomized Phase IIIb Study. Pediatr Infect Dis J. 2012;31(5). doi:10.1097/INF.0b013e3182490a2c 7. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and Efficacy of the Pentavalent Human-Bovine (WC3) Reassor tant Rotavirus Vaccine in Healthy Premature Infants. Pediatr Infect Dis J. 2007;26(12):1099-1104. doi:10.1097/INF.0b013e31814521cb 8. Omeñaca F, Vázquez L, Garcia-Corbeira P, et al. Immunization of preterm infants with GSK’s hexavalent combined diphtheria-tetanus-acellular per tussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine . Published online 2018. doi:10.1016/j.vaccine.2018.01.005 9. Bruijning-Verhagen PCJ. RIVAR study protocol. Published 2014. Accessed November 17, 2020. https://www.trialregister.nl/trial/5213 10. Simmonds MK, Armah G, Asmah R, et al. New oligonucleotide primers for P-typing of rotavirus strains: Strategies for typing previously untypeable strains. J ClinVirol. 2008;42(4):368- 373. doi:10.1016/j.jcv.2008.02.011 11. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine . 2010;28(47):7507- 7513. doi:10.1016/J.VACCINE.2010.09.004 12. Maes P, Matthijnssens J, Rahman M, Van Ranst M. RotaC: A web-based tool for the complete genome classification of group A rotaviruses. BMC Microbiol. 2009;9:2-5. doi:10.1186/1471-2180-9-238 13. Knol MJ, Le Cessie S, Algra A,Vandenbroucke JP, Groenwold RHH. Overestimation of risk ratios by odds ratios in trials and cohor t studies: Alternatives to logistic regression. CMAJ. Published online 2012. doi:10.1503/cmaj.101715 14. Hoftiezer L, Dijs-Elsinga J, van Dillen J, et al. Perined population curves. Published 2018. Accessed May 28, 2019. https://www.perined.nl/publicaties1/geboortegewichtcurven 15. World population by Country 2020. Accessed September 11, 2020. https:// worldpopulationreview.com/continents/capitals/europe 16. International Vaccine Access Center. Current Rotavirus Vaccine Intro status. Bloom Sch Public Heal. 2018;([cited 2019]). https://view-hub.org/map/?set=current-vaccine-intro- status&category=rv&group=vaccine-introduction 17. Soares-Weiser K, Bergman H, Henschke N, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: Vaccines in use. Cochrane Database Syst Rev . 2019;2019(3).